Cargando…
Management of Ocular Toxicity in Patients Receiving Belantamab Mafodotin
While significant strides have been made in the treatment of multiple myeloma, treatment options remain limited and definite, and most patients ultimately succumb to their disease. The urgency for more treatment modalities remains, as patients who are refractory to proteasome inhibitors, immunomodul...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Harborside Press LLC
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258852/ https://www.ncbi.nlm.nih.gov/pubmed/37313276 http://dx.doi.org/10.6004/jadpro.2023.14.4.4 |